Longevity & Cardiovascular Health
NOVOS Core is a longevity formulation studied in a randomized, double-blind, placebo-controlled human trial for its effects on measures of healthy vascular function: arterial flexibility, endothelial responsiveness, and blood pressure within the normal range.
Studied in generally healthy adults 40+ · University of Surrey · NCT06145087
Placebo-adjusted differences at six months in biomarkers of vascular function. NOVOS Core is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease.
One daily drink. Recommended by 2,000+ verified doctors & clinicians.
As featured in
NOVOS Core
No isolated single ingredient, no research-only version. The clinical study evaluated the complete NOVOS Core product as sold, one flavored powder sachet mixed into water, once a day.
Why age 30 changed everything
In 2026, updated ACC/AHA guidance recommends estimating both 10-year and 30-year cardiovascular risk beginning at age 30. The shift reflects a simple reality of the science: cardiovascular disease develops over decades, and long-term risk becomes meaningful long before it becomes visible.
Arterial changes can begin decades before anything is detectable in ordinary bloodwork or felt as a symptom.
2026 ACC/AHA guidance recommends estimating both 10-year and 30-year cardiovascular risk starting at age 30.
Conventional attention often begins only once risk markers move, years after vascular changes have accumulated.
This section describes published clinical-guideline recommendations for risk estimation. It is general educational information, not medical advice, and NOVOS Core is not intended to diagnose, treat, cure, or prevent cardiovascular disease. Talk with a qualified healthcare professional about your own cardiovascular risk.
Invisible infrastructure
Roughly 60,000 miles of blood vessels reach nearly every cell you have. When researchers study vascular function, they're studying the delivery system that supports how the rest of the body performs.
The brain is one of the most perfusion-dependent organs in the body, relying on steady cerebral blood flow.
Working muscle depends on how effectively vessels dilate to deliver oxygen and nutrients on demand.
Cellular energy production requires reliable oxygen delivery through the smallest capillaries.
Dermal microcirculation supports nutrient delivery to skin tissue and normal skin function.
Retinal tissue is served by an exceptionally fine vascular network sensitive to blood-flow changes.
Filtration depends on vascular flow, the kidneys receive a substantial share of cardiac output.
These descriptions explain the physiological role of circulation in the body. They are not claims that NOVOS Core treats, prevents, or improves any specific organ condition.
What the researchers measured
Rather than relying on self-reported feelings, the trial used objective vascular biomarkers routinely used in cardiovascular research.
How well an artery widens when blood flow increases, a non-invasive measure of endothelial function.
The endothelium is the single-cell lining that governs how vessels relax, dilate, and respond to demand.
+2.9pts
placebo-adjusted difference at 6 months
The speed at which a pressure wave travels along the arteries. Stiffer arteries transmit it faster.
Arterial flexibility is one of the most studied structural properties of the vascular system.
−1.18m/s
placebo-adjusted difference at 6 months
The pressure inside arteries when the heart contracts, measured here entirely within the normal range.
Blood pressure within a healthy range is part of normal cardiovascular function.
−6.1mmHg
placebo-adjusted difference at 6 months
*Participants began and remained within the normal blood-pressure range. Trial did not assess cardiovascular events or disease prevention. Manuscript currently under peer review.
These are biomarkers of vascular function. Biomarker changes are not the same as reduced disease risk, and the trial did not evaluate heart attacks, strokes, cardiovascular mortality, or disease incidence.
The clinical study
The study was conducted by researchers at the University of Surrey and led by Professor Christian Heiss, a vascular medicine researcher and one of the field's most-published authors on flow-mediated dilation methodology.
Faculty of Health & Medical Sciences
Results are available as an SSRN preprint. The manuscript is currently under peer review, and findings should be interpreted accordingly.
“Very few supplements are ever tested this way: as the complete finished product, in a randomized placebo-controlled design, using objective vascular measurements.”
Professor Christian Heiss · Principal investigator, University of Surrey
Statement refers to study methodology. It is not a claim that NOVOS Core treats or prevents disease.
Primary measure
FMD was measured at baseline, one hour after a single dose, and again after six months of daily use in a fasted state. Bars show 95% confidence intervals.
Data from the randomized, double-blind, placebo-controlled University of Surrey trial of NOVOS Core in generally healthy adults aged 40+ (SSRN preprint, manuscript under peer review). FMD is a biomarker of endothelial function; a change in FMD is not a measure of disease risk, and the study did not evaluate cardiovascular events. These values do not indicate that vascular age was reversed by any specific number of years.
Context, not competition
Reported improvements in flow-mediated dilation across separate published studies. These are independent studies in different populations, read them as context for scale, not as a ranking.
percentage points
These values come from separately published studies and are not head-to-head comparisons. Populations, baseline health, intervention durations, study designs, and measurement methods differ. The chart contextualizes reported effect sizes and does not establish that NOVOS Core is clinically superior to exercise, diet, or any other intervention.
Exercise, dietary quality, smoking avoidance, healthy sleep, and appropriate medical management remain foundational components of cardiovascular health.
An honest nuance
The trial did not find meaningful changes in lipid markers, even while FMD, PWV, and systolic blood pressure differed from placebo. We think that's worth highlighting.
Lipid panels and vascular-function measures describe different aspects of cardiovascular biology. One reflects circulating cholesterol carriers; the other reflects how arteries physically respond and behave. They are complementary views, and neither replaces the other. FMD, PWV, and blood pressure measure the actual organ function, whereas molecules like LDL are associated with damage over the long term at high exposure.
NOVOS Core is not a lipid-lowering product and should not be used in place of cholesterol management prescribed by a healthcare professional.
Why a formulation, not an ingredient
NOVOS Core combines 12 ingredients selected to address multiple biological pathways associated with aging. What was tested clinically was the complete formulation, not any single component in isolation.
Ingredients with research related to nitric-oxide signaling and the normal processes involved in healthy vessel dilation and blood-flow regulation.
Polyphenols and antioxidant nutrients that help support normal cellular defenses against oxidative stress.
Ingredients researched in relation to cellular stress-response, metabolic, and other biological pathways involved in healthy aging.
Ingredients researched for their roles in normal protein maintenance and biological processes relevant to healthy tissue structure over time.
Minerals with established roles in normal muscle function, electrolyte balance, and healthy vascular tone, including magnesium.
Nutrients involved in normal collagen formation and the maintenance of healthy connective tissue.
These pathways reflect established nutrient functions and ingredient-level research used to inform the formulation. The NOVOS Core clinical trial evaluated the finished formula and did not determine which biological mechanism or individual ingredient was responsible for the observed vascular effects.
Award-winning formulation
Available at
1,331 customer reviews of NOVOS Core
Recommended by 2,000+ verified doctors & clinicians
Over 10 million NOVOS doses served
35,000+ people investing in their longevity
“I don't think I've felt this good in years. Energy from morning to bedtime, and I like knowing the product itself has been studied rather than just its ingredients.”
Julie G.
“A week in and I'm already impressed. I feel calm, clear-headed, and I have more endurance into the evening hours.”
Beth P.
“I've been taking NOVOS Core for over a year now. I've never felt more energized or focused throughout the day.”
Grace D.
“My focus has sharpened and my energy level has markedly improved. In general I feel more optimistic about the decades ahead.”
Phillip S.
Individual experiences with dietary supplements vary and are not clinical evidence. Customer reviews describe personal experience and do not establish that NOVOS Core treats, prevents, or cures any condition.
Scientific advisory board
Dr. George Church, PhD
Harvard Medical School & MIT Professor
Dr. Pamela Maher, PhD
University of British Columbia, Salk Institute for Biological Studies
Dr. J Pedro de Magalhaes, PhD
Harvard Medical School, University of Birmingham
Dr. Oliver Medvedik, PhD
Harvard Medical School, The Cooper Union
Dr. Avi Rosenbaum, PhD
Harvard Medical School
Dr. Robert Lufkin, MD
USC School of Medicine
Advisors contribute scientific guidance to NOVOS. Institutional affiliations are listed for identification only and do not imply endorsement by those institutions.
Start today
Choose your plan
Flavor
Start my longevity plan$950 billed upfront · Secure checkout on novoslabs.com
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Straight answers
Cardiovascular disease typically develops over decades. New 2026 ACC/AHA guidance now recommends estimating both 10- and 30-year cardiovascular risk beginning at age 30. Supporting cardiovascular health early is about maintaining healthy function and understanding long-term risk before disease becomes clinically obvious.
No. NOVOS Core is a dietary supplement designed to support healthy aging and normal vascular function. It is not intended to diagnose, treat, cure, or prevent cardiovascular disease, heart attack, stroke, hypertension, or any other disease.
Yes. The complete finished NOVOS Core formulation was evaluated in a randomized, double-blind, placebo-controlled human trial conducted by researchers at the University of Surrey in generally healthy adults aged 40+. The study evaluated vascular-function biomarkers including FMD, PWV, and systolic blood pressure.
The manuscript is currently under peer review. The trial did not assess heart attacks, strokes, cardiovascular mortality, or disease prevention.
Flow-mediated dilation measures how well an artery expands in response to increased blood flow. It is widely used in vascular research as a non-invasive measure of endothelial function. NOVOS Core showed a +2.9 percentage-point placebo-adjusted difference at six months.
Pulse wave velocity measures the speed at which a pressure wave travels through the arteries. Stiffer arteries transmit the wave faster. NOVOS Core showed a −1.18 m/s placebo-adjusted difference at six months.
Population data suggest PWV tends to worsen with age, but the NOVOS result should not be interpreted as proof that Core reversed a specific number of years of aging.
The study observed a −6.1 mmHg placebo-adjusted difference in systolic blood pressure at six months. Importantly, participants began and remained within the normal blood-pressure range. NOVOS Core should not be presented as a treatment for hypertension.
The study did not find meaningful lipid changes, despite differences in FMD, PWV, and systolic blood pressure versus placebo. Cholesterol-related biomarkers and vascular-function biomarkers measure different aspects of cardiovascular health and should be viewed as complementary.
No. The clinical trial measured vascular-function biomarkers. It was not designed or powered to determine whether NOVOS Core reduces heart attacks, strokes, cardiovascular mortality, or cardiovascular-disease incidence.
No. If your healthcare professional has prescribed medication, do not stop or replace it with NOVOS Core without discussing it with them. Dietary supplements do not replace medically indicated treatment.
Evidence-based fundamentals include regular physical activity, a heart-healthy dietary pattern such as Mediterranean-style eating, healthy sleep, avoiding tobacco, maintaining metabolic health, knowing relevant cardiovascular risk markers, and following appropriate medical guidance. NOVOS Core should be viewed as an additional layer, not a replacement for these fundamentals.
Six months of daily supplementation.
Generally healthy adults aged 40 and older. The trial's findings should not be extrapolated as direct clinical proof in younger adults.
Longevity & Cardiovascular Health
NOVOS Core supports healthy vascular function as part of a longevity-first routine, studied as the finished product in a randomized, placebo-controlled trial.
Recommended by 2,000+ verified doctors & clinicians · University of Surrey RCT · NCT06145087
